GLAND PHARMA LIMITED Fair Value
GLAND · Healthcare · Current price ₹2,888.1
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹608 | 11% ROE fading to 12% over ~10 yrs, on ₹629 book |
| Relative P/E | ₹2,438 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹939 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,834 | Street consensus 12-month target price |
Is GLAND PHARMA LIMITED undervalued?
DocStoX estimates the fair value of GLAND PHARMA LIMITED at ₹1,472 per share, versus the current market price of ₹2,888. That puts the stock about -49.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹608), Relative P/E (₹2,438), Graham floor (₹939), Analyst target (₹2,834). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹608 (bear) to ₹1,472 (base) to ₹2,834 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on GLAND PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.